Sustained compensatory p38 MAPK signaling following treatment with MAPK inhibitors induces the immunosuppressive protein CD73 in cancer: combined targeting could improve outcomes.
Sign Up to like & getrecommendations! Published in 2021 at "Molecular oncology"
DOI: 10.1002/1878-0261.13046
Abstract: RAS-MAPK signaling promotes immune evasion and cancer cell survival, and MAPK inhibitors (MAPKi) are frequently used as cancer therapies. Despite progress elucidating the direct effects of MAPKi on immune cells, their indirect effect on the… read more here.
Keywords: treatment; mapki; cd73; mapk signaling ... See more keywords
PO-241 Targeting fatty acid oxidation and glycolysis to overcome drug resistance to MAPK inhibitors
Sign Up to like & getrecommendations! Published in 2018 at "ESMO Open"
DOI: 10.1136/esmoopen-2018-eacr25.274
Abstract: Introduction Malignant melanoma is an aggressive tumour characterised by poor prognosis and therapeutic resistance. It is partly driven by the MAPK signalling pathway, providing a rationale for the development of inhibitors (MAPKi) targeting key components… read more here.
Keywords: melanoma; glycolysis; mapki; fatty acid ... See more keywords
A Novel Mitochondrial Inhibitor Blocks MAPK Pathway and Overcomes MAPK Inhibitor Resistance in Melanoma
Sign Up to like & getrecommendations! Published in 2019 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-19-0836
Abstract: Purpose: The purpose of this study is to determine if inhibition of mitochondrial oxidative phosphorylation (OxPhos) is an effective strategy against MAPK pathway inhibitor (MAPKi)–resistant BRAF-mutant melanomas. Experimental Design: The antimelanoma activity of IACS-010759 (OPi),… read more here.
Keywords: mapki; mapk pathway; melanoma; vivo ... See more keywords